Online inquiry

IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13575MR)

This product GTTS-WQ13575MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13575MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5075MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ15415MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA TSR-022
GTTS-WQ3501MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ323MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 1F5
GTTS-WQ4499MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ14644MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ12351MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA N63Ab
GTTS-WQ10833MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA M7824
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW